TransThera Sets 18 June 2026 Virtual AGM; Shareholders to Vote on FY 2025 Results, Auditor Renewal and Supervisory Committee Cancellation

Bulletin Express05-26

TransThera Sciences (Nanjing), Inc. (“TransThera-B”) has convened its 2025 annual general meeting (AGM) for 10:30 a.m. on 18 June 2026. The meeting will be held entirely online via the Vistra eVoting Portal, and shareholders may appoint proxies or participate directly through the e-meeting system.

Key matters up for approval (14 resolutions in total) include:

1. FY 2025 Operating Results • Board Report and Supervisory Committee Report for 2025. • Audited consolidated financial statements and full 2025 Annual Report. • Acknowledgement that uncovered losses exceed one-third of paid-up share capital. • Proposed 2025 profit-distribution plan.

2. Governance & Appointments • Re-appointment of Ernst & Young as external auditor for 2026; Board authorised to determine remuneration. • 2026 remuneration packages for directors and supervisors. • Election of Mr Feng Weibo as independent non-executive director for the new Board term.

3. Capital Management Mandates • General mandate authorising the Board to allot, issue and deal with additional shares, including treasury stock transactions. • Authority to repurchase H-shares and to extend the share-issuance mandate by the amount of repurchased shares.

4. Structural Change • Proposal to cancel the Supervisory Committee, accompanied by amendments to the company’s business scope and Articles of Association.

Proxy Procedures Shareholders may submit proxy forms to Tricor Investor Services Limited (H-share register) or the company’s Nanjing head office (unlisted shares) by 10:30 a.m. on 17 June 2026 (Hong Kong time). Each share carries one vote. Joint holders will receive a single set of login credentials for the eVoting system.

The AGM documentation emphasises electronic participation; shareholders choosing to attend virtually will have their previously lodged proxy forms automatically revoked upon online voting.

Approval of the outlined resolutions will finalise TransThera’s FY 2025 reporting cycle, confirm key appointments and mandates for 2026, and determine the proposed removal of the Supervisory Committee alongside revisions to governing documents.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment